Shared Medical Decision Making in the Prophylactic Treatment of Bipolarity
This study is active but not recruiting. It focuses on bipolarity and currently lists study information in France.
BipolarityOtherOver 18 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Shared-decision making process may be useful for adults experiencing bipolarity.
What would participation involve?
Participants may complete study activities around Shared-decision making process, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in France.
Who is it mainly for?
This study appears to be mainly for adults with bipolarity.
What should you check before joining?
Ask about whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
France · 16 sites
Ch Beziers
Béziers
Site status: Not listed — confirm with the team
CH Charles Perrens
Bordeaux
Site status: Not listed — confirm with the team
CH le Vinatier
Bron
Site status: Not listed — confirm with the team
CHU de Clermont Ferrand - Hôpital Gabriel-Montpied
Clermont-Ferrand
Site status: Not listed — confirm with the team
Chu Gabriel Montpied Clermont Ferrand
Clermont-Ferrand
Site status: Not listed — confirm with the team
CH Sainte-Marie de Clermont-Ferrand
Clermont-Ferrand
Site status: Not listed — confirm with the team
APHP - Centre Hospitalier Henri Mondor
Créteil
Site status: Not listed — confirm with the team
CHU de Grenoble - Hôpital Albert Michallon
Grenoble
Site status: Not listed — confirm with the team
CH Limoges
Limoges
Site status: Not listed — confirm with the team
APHM - Hôpital Sainte-Marguerite
Marseille
Site status: Not listed — confirm with the team
CHU de Montpellier - Hôpital Lapeyronie
Montpellier
Site status: Not listed — confirm with the team
CHU Nancy
Nancy
Site status: Not listed — confirm with the team
CHU Nantes
Nantes
Site status: Not listed — confirm with the team
Clinique des troubles thymiques
Nîmes
Site status: Not listed — confirm with the team
CHU Nimes
Nîmes
Site status: Not listed — confirm with the team
APHP - Hôpital Saint Louis-Lariboisière-Fernand-Widal
Paris
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring observational follow-up for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Why is the study type not clearly categorized?
The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.
Who might this study be for?
This study may concern people with bipolarity; age range: Over 18 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What risks or points should I check?
The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Centre Hospitalier Universitaire de Nīmes, which appears to be unknown or unclear. The listed contact or investigator is Centre Hospitalier Universitaire de Nīmes, affiliated with Centre Hospitalier Universitaire de Nīmes. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
The registry lists this study as recruiting. Study locations are listed in France. Confirm recruitment at each site. It is testing genetic Variants Identified for treatment-resistant depression.